Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C9WN
|
|||
| Former ID |
DIB006867
|
|||
| Drug Name |
MKC-1106-PP
|
|||
| Synonyms |
E-PRA; E-PSM; Melanoma vaccine, CTL Immunotherapies; Peptide DNA vaccine (cancer), MannKind; Synchrovax vaccine (melanoma), CTL Immunotherapies; Peptide DNA vaccine (PRAME, PSMA), MannKind; [10-Val]PSMA(288-297); Peptide DNA vaccine (preferential antigen of melanoma, prostate-specific membrane antigen), MannKind; [2-norVal, 10-norLeu]PRAME(425-433)
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
CTL Immunotherapies Corp
|
|||
| Structure |
 |
Download2D MOL |
||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00423254) Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.